ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

Completed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).

Key facts

Study ID

NCT00004582

Run by

ViRx

Last updated by the study team

2005-06-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this study if they:
• Are HIV-positive.
• Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml.
• Have been receiving stable (no changes) anti-HIV treatment that includes at least 1 PI for at least 8 weeks prior to study entry.
• Have received more than 1 PI for at least 12 weeks each at some time in the past.

You may not qualify if…

• Patients will not be eligible for this study if they:
• Have had any active opportunistic (AIDS-related) infections within the past 30 days.
• Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine, nevirapine, or efavirenz.
• Have received certain medications.
• Are pregnant or breast-feeding.
• Abuse alcohol or drugs.

Where it is running

• ViRx Inc — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.